Our R&D portfolio consists of antiviral compounds. What makes us unique is our chemical process technology for the thionation of drug molecules, JBR, named after our co-founder Jan Bergman, Late Prof. Emeritus at the Karolinska Institute in Stockholm. Prof. Bergman has played a significant role in the development of Vironova Medical with extensive experience in organic molecules and their application in drug design.
Vironova Medical's pipeline of pharmaceutical applications
WHAT MAKES US UNIQUE IS OUR CHEMICAL PROCESS TECHNOLOGY FOR THIONATION OF DRUG MOLECULES; JBR.